Oncotype DX Score is a Genomic test that evaluates the Expression of 21 genes to predict the likelihood of Breast Cancer Recurrence and the potential Benefit of chemotherapy in early-stage hormone receptor-positive, HER2-negative Breast Cancer patients. This score helps guide Personalized Treatment Plans by Categorizing patients into low, intermediate, or High risk for recurrence.